From the Journals

Body Roundness Index Predicts Mortality: Key Risks Revealed

A recent study found that extreme Body Roundness Index levels significantly increase the risk of all-cause mortality among US adults, highlighting the importance of this measure in health assessments.

Share

A recent cohort study published in JAMA Network Open found an association between both low and high body roundness index (BRI) levels and an increased risk of all-cause mortality among U.S. adults. The study, which included a nationally representative cohort of 32,995 U.S. adults aged ≥ 20 years, utilized data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999 to 2018. It identified a U-shaped association between BRI and all-cause mortality, with adults exhibiting the lowest and highest BRI levels experiencing significantly increased mortality risk. These findings suggest that BRI could serve as a useful anthropometric measure for estimating mortality risk.

Original Source(s)

Body Roundness Index Predicts Mortality: Key Risks Revealed

A recent study found that extreme Body Roundness Index levels significantly increase the risk of all-cause mortality among US adults, highlighting the importance of this measure in health assessments.

  • by Conexiant News Staff

  • June 5, 2024

  • 2 min

Related Content

Oral GLP-1s Won’t Win on Convenience – They’ll Win on CMC 

GLP-1 peptides validated the science. CMC will validate the small molecule modality for GLP-1 efficacy, scalability, and access.

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.